Li Cong, Chen Jian, Yang Fan, Huang Yu, Hua Guangyao, Kuang Yu, Cai Dongqin, Liu Shunming, He Xue, Wang Yan, Peng Jingyan, Jiang Jianrong, Du Zhenchao, Huang Tengda, Peng Zhishen, Li Heng, Liu Lei, Luo Jianfang, Yang Xiaohong, Yu Honghua
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Sciences, Guangzhou, China; Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academic of Medical Sciences), Southern Medical University, Guangzhou, China.
Public Health. 2025 Oct;247:105883. doi: 10.1016/j.puhe.2025.105883. Epub 2025 Jul 28.
Aortic aneurysm (AA) is a life-threatening disease with high mortality. Up-to-date, information on AA burden in China is limited, which is required for health-care planning, resource allocation, and disease prevention. This study investigated the burden of AA in China from 1990 to 2021, and then compared it with other G20 countries.
A comprehensive analysis of the Global Burden of Disease Study 2021 data.
Estimates of mortality and years of life lost (YLLs) for AA were generated from the Global Burden of Diseases Study (GBD) 2021. Mortality was estimated from vital registration data with the cause of death ensemble model, and YLLs were calculated with the use of standard GBD lifetables. The age-specific and sex-specific patterns, attributable risk factors, and trends regarding the burden of AA in China as well as other G20 nations were summarized.
In 2021, there were an estimated 9.04 thousand (95 % uncertainty interval 7.04 to 11.58) deaths due to AA in China, representing a 241.29 % increase since 1990. The age-standardised death rate was 0.46 per 100,000 (0.36-0.59), with a 37.27 % increase from 1990 to 2021. The 2021 YLLs count was 242.11 thousand (185.41-315.41) in China, an increase of 180.74 %, with an age-standardised YLLs rate of 12.4 per 100,000 (9.54-16.09), an increase of 38.89 % since 1990. Both mortality and YLLs were higher in males than in females within all age groups. An upward trend with age in mortality and YLLs was observed. In 2021, smoking remained a major attributable risk factor for AA burden in Chinese males, but high systolic blood pressure was the major factor in females. Furthermore, high body-mass index has risen to the top three risk factors both in males and females. Compared with G20 countries, China was ranked 10th in deaths number in 1990 and then increased to 6th in 2021, and YLLs also increased from 5th to 4th. From 1990 to 2021, unlike China, most G20 countries presented decreased age-standardised rates of death and YLLs, with the largest decrease in Australia, Canada, United Kingdom, and United States of America.
AA remains a serious threat to public health in China, especially for the male and elderly population. Smoking, high systolic blood pressure, and high body-mass index were major attributable risk factors for AA in China. Targeted and cost-effective interventions are urgently needed in China to reduce this burden.
主动脉瘤（AA）是一种危及生命且死亡率很高的疾病。目前，中国关于AA负担的信息有限，而这对于医疗保健规划、资源分配和疾病预防来说是必需的。本研究调查了1990年至2021年中国AA的负担情况，然后将其与其他二十国集团（G20）国家进行比较。
对《2021年全球疾病负担研究》数据进行全面分析。
AA的死亡率和寿命损失年数（YLLs）估计值来自《2021年全球疾病负担（GBD）研究》。死亡率通过死因汇总模型根据人口动态登记数据进行估计，YLLs则使用标准GBD生命表进行计算。总结了中国以及其他G20国家AA负担的年龄和性别特异性模式、可归因风险因素及趋势。
2021年，中国估计有9040例（95%不确定区间为7040至11580例）死于AA，自1990年以来增长了241.29%。年龄标准化死亡率为每10万人0.46例（0.36 - 0.59例），1990年至2021年增长了37.27%。2021年中国的YLLs数为24.21万（18.54万至31.54万），增长了180.74%，年龄标准化YLLs率为每10万人12.4例（9.54至16.09例），自1990年以来增长了38.89%。在所有年龄组中，男性的死亡率和YLLs均高于女性。观察到死亡率和YLLs随年龄呈上升趋势。2021年，吸烟仍是中国男性AA负担的主要可归因风险因素，但高收缩压是女性的主要因素。此外，高体重指数已升至男性和女性的三大风险因素之列。与G20国家相比，中国1990年的死亡人数排名第10，到2021年升至第6，YLLs也从第5升至第4。1990年至2021年，与中国不同，大多数G20国家的年龄标准化死亡率和YLLs率呈下降趋势，澳大利亚、加拿大、英国和美国下降幅度最大。
AA仍然是中国公共卫生的严重威胁，尤其是对男性和老年人群体。吸烟、高收缩压和高体重指数是中国AA的主要可归因风险因素。中国迫切需要有针对性且具有成本效益的干预措施来减轻这一负担。
